GSK Q3 turnover beats, affirms FY26 guidance, flags vaccine weakness

GSK reported Q3 turnover of £8.9B, above the £8.82B estimate, up 5% CER, with core EPS of 54.6p. The company affirmed FY26 guidance of 3%-5% turnover growth and 7%-9% core EPS growth. Specialty Medicines grew 15% CER, but Vaccines fell 2%. GSK announced three new US approvals and reiterated a 2031 sales outlook above £40B.